Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pravitinib - Tactical Therapeutics

Drug Profile

Pravitinib - Tactical Therapeutics

Alternative Names: CAI orotate; Carboxyamidotriazole orotate; CTO

Latest Information Update: 02 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tactical Therapeutics
  • Developer Duke University Medical Center; Tactical Therapeutics
  • Class Amides; Antineoplastics; Small molecules; Triazoles
  • Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Calcium channel antagonists; Cyclo-oxygenase 2 inhibitors; Epidermal growth factor receptor antagonists; Growth inhibitors; Interleukin 2 inhibitors; Nitric oxide synthase type I inhibitors; Phosphotransferase inhibitors; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors; Vascular endothelial growth factor A expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioma
  • Phase I Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Small cell lung cancer
  • Preclinical Malignant melanoma; Prostate cancer
  • Discontinued Age-related macular degeneration

Most Recent Events

  • 02 Jul 2018 Tactical Therapeutics has patent protection for pravitinib in USA, Australia, Brazil, Canada, Chile, China, EU, Honk Kong, India, Inodnesia, Isarel, Japan, South Korea, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa, Thailand, Ukraine, Vietnam and Africa (Tactical Therapeutics website, July 2018)
  • 02 Jul 2018 Discontinued - Phase-II for Age-related macular degeneration in Australia and New Zealand (PO)
  • 02 Jul 2018 Phase-I clinical trials in Colorectal cancer (Combination therapy, Metastatic disease) in USA (PO) (Tactical Therapeutics pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top